Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007, for CVS Caremark Corporation (formerly CVS Corporation). The reporting period is significantly impacted by the completion of the Caremark Merger on March 22, 2007, which combined CVS's retail pharmacy business with Caremark's pharmacy benefit management (PBM) operations. The consolidated results include 91 days of Caremark's operations for the 13-week period and 101 days for the 26-week period.
Key Financial Metrics
| Metric (26 Weeks Ended June 30, 2007) | Value (in millions) |
|---|---|
| Net Revenues | $33,891.9 |
| Gross Profit | $7,461.7 |
| Operating Profit | $2,046.3 |
| Net Earnings | $1,132.5 |
| Diluted EPS | $0.91 |
| Net Cash from Operating Activities | $1,427.2 |
| Total Assets | $54,606.1 |
| Total Debt (Short-term + Long-term) | $9,396.1 |
| Cash and Cash Equivalents | $812.3 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by $13.3 billion (65%) for the 26 weeks ended June 30, 2007, compared to the same period in 2006. This was primarily driven by the Caremark Merger ($9.4 billion increase) and the prior acquisition of the Standalone Drug Business ($2.1 billion increase).
- Profitability: Net earnings rose $465.0 million (69.7%) to $1.13 billion. Operating profit increased $890.8 million (77.1%) to $2.05 billion.
- Balance Sheet Expansion: Total assets more than doubled from $20.6 billion to $54.6 billion, largely due to the recording of Caremark's assets, including $20.2 billion in goodwill and $10.2 billion in intangible assets.
- Debt Levels: Long-term debt increased significantly from $2.9 billion to $8.4 billion to fund the merger and share repurchase programs.
Guidance, Outlook, and Risks
Management Commentary: Management expects to achieve significant benefits from purchasing scale and operating synergies, including decreased overhead and prescription dispensing costs. The company anticipates an effective annual income tax rate of approximately 39.7% for the full year 2007.
Capital Allocation: The company authorized a $5.0 billion share repurchase program in May 2007. It executed a $2.5 billion Accelerated Share Repurchase (ASR) agreement and a tender offer, repurchasing approximately 72 million shares in the quarter.
Risks and Contingencies:
- Integration Risk: Success depends on the ability to integrate Caremark's operations and realize projected synergies.
- Regulatory and Legal: The company faces ongoing litigation regarding stock option backdating (settled pending court approval), antitrust claims regarding PBM practices, and government investigations into Medicaid claims processing.
- Reimbursement Pressure: Continued efforts by third-party payors to reduce prescription drug costs and generic reimbursement rates pose a risk to gross profit margins.
Investor Verification Checklist
- Verify the final valuation of goodwill and intangible assets recorded in the Caremark Merger, as current values are preliminary.
- Monitor the realization of projected operating synergies and cost savings from the merger integration.
- Review the status of pending litigation, specifically the stock option backdating settlement and antitrust class actions.
- Assess the impact of generic drug conversion rates on pharmacy gross profit margins in both retail and PBM segments.
- Track the company's ability to maintain investment-grade credit ratings (currently Baa2/BBB+) amidst increased leverage.